The outcome of regulatory inspections is critical to an organization’s success. The FDA performs inspections to check that companies are maintaining compliance with applicable regulations and quality standards. Though you do your best to avoid it, receiving a 483 or Warning Letter is inevitable. It’s important to take the observations very seriously because you only have 15 days to submit the subsequent responses.
But ensuring that you are aware and understand what the regulatory agency is expecting in the response can be a challenge. What should you include? What are the risks of not submitting an appropriate response?
This 90-minute course will discuss the importance of developing and submitting a robust, timely response to FDA 483 observations or warning letters; as well as, educate the audience on the essential elements of a thorough response. Additionally, this course will review the proper structure of the response to ensure the regulatory agency’s expectations are met and the submission process.
LEARNING OBJECTIVES
At the completion of this session, you will be able to:
- Identify timelines and potential regulatory outcomes of not submitting an appropriate response
- Review the components necessary to develop a thorough response
- Utilize a response checklist
- Evaluate recent Regulatory observations and review associated responses
- Recognize the process for submitting the response to the regulatory agency
- Discuss when and how to provide follow-up updates to the regulatory agency post the initial response
- Develop post-response outcomes
WHO WILL BENEFIT?
This course will be valuable to anyone engaged in the development, manufacturing, sale, or distribution of FDA-regulated healthcare products. Additionally, this course will provide a good primer for those involved in writing observation responses. This includes personnel in:
- Quality
- Manufacturing
- Engineering
At the completion of this session, you will be able to:
- Identify timelines and potential regulatory outcomes of not submitting an appropriate response
- Review the components necessary to develop a thorough response
- Utilize a response checklist
- Evaluate recent Regulatory observations and review associated responses
- Recognize the process for submitting the response to the regulatory agency
- Discuss when and how to provide follow-up updates to the regulatory agency post the initial response
- Develop post-response outcomes
This course will be valuable to anyone engaged in the development, manufacturing, sale, or distribution of FDA-regulated healthcare products. Additionally, this course will provide a good primer for those involved in writing observation responses. This includes personnel in:
- Quality
- Manufacturing
- Engineering
Speaker Profile
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
Upcoming Webinars
Data Integrity and Privacy: Compliance with 21 CFR Part 11,…
Design Verification, Validation and Testing for Medical Dev…
Project Management for Non-Project Managers - How to commun…
Why EBITDA Doesn't Spell Cash Flow and What Does
FFIEC BSA/AML Examination Manual: What Compliance Officers …
Harassment, Bullying, Gossip, Confrontational and Disruptiv…
Employee or Independent Contractor – U.S DOL Announces 2024…
How to Survive an Emotionally Toxic Workplace
Ensuring Safe and Effective Pharmaceutical Products: A Comp…
Best Practices in Complaint Management for Regulatory Compl…
Human Factors Usability Studies Following ISO 62366 and FDA…
Updated Metro 2®, e-OSCAR and the New Tougher FCRA/CFPB Com…
Gossip-Free: Leadership Techniques to Quell Office Chatter
Tattoos, hijabs, piercings, and pink hair: The challenges …
Embracing Diversity and Inclusion in Talent Acquisition
Form W-9 Compliance to Avoid Penalties: TIN Verification, B…
Divorce, Adoption and Other Special Tax Topics
Understanding and Analyzing Financial Statements
Setting up Quality System for FDA Regulated Products: Tips …
Is Your Culture Working For or Against Your Success? If You…
Design History File (DHF), the Device Master Record (DMR) a…
With Mandatory Paid Leave Gaining Ground Is It Time To Do A…
The Five Cs Of Commercial Credit: The Basic Elements Of Cre…
Marketing to Medicare or Medicaid Beneficiaries - What You …
Documenting Misconduct that Will Stand Up in Court
Sunshine Act Reporting - Clarification for Clinical Research
Stress, Change And Team Resilience Through Humor: An Intera…
FDA Regulation of Artificial Intelligence/ Machine Learning
Managing Toxic & Other Employees Who have Attitude Issues
Pharma 4.0: Next Generation Technology Approach to GxP Prod…
Excel - Lists and Tables - A Beginner's Guide to Managing L…
Managing Complex Projects - Project Management
Patient Gifts, Discounts and Freebies: What You Can and Can…
All About Civility - Eliminating a Culture of Gossip Rumors…
From Challenges to Compliance: Understanding Dietary Supple…
Improving Employee Engagement & Retention Through Stay Inte…
How To Conduct An Internal Harassment And Bullying Investig…
Using Behavior Based Interviewing for Finding the Best Matc…
The Anti-Kickback Statute: Enforcement and Recent Updates
Leadership: Strategic Planning and Decision Making
Bootcamp for New Managers and Supervisors: Avoid These 7 Mi…
Emotional Intelligence: Mastering the Emotions of Great Lea…
Do's and Don'ts of Documenting Employee Behaviour, Performa…
How to Conduct Exit Interviews - Implementing and Enhancing…